2 results
Approved WMOCompleted
To evaluate the safety and efficacy of subcutaneousbelimumab (GSK1550188) and intravenous rituximab coadministrationin subjects with primary Sjögren*s syndrome.
Approved WMORecruiting
Primary Objective: Evaluate if testosterone replacement therapy (TRT) in (a)symptomatic testosterone deficient men with prostate cancer undergoing Radical Prostatectomy (RP), leads to better outcomes in the domain of sexual functioning 12 months…